The addition of ABCD1 to the ACMG’s list of recommended secondary findings marks a significant shift in how X-linked adrenoleukodystrophy (X-ALD) is detected across the lifespan. With newborn screening already identifying affected infants in most U.S. states, the expansion into secondary findings ...